Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.
2.

MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection.

Seo SU, Kwon HJ, Song JH, Byun YH, Seong BL, Kawai T, Akira S, Kweon MN.

J Virol. 2010 Dec;84(24):12713-22. doi: 10.1128/JVI.01675-10. Epub 2010 Oct 13.

3.

Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.

Goff PH, Hayashi T, Martínez-Gil L, Corr M, Crain B, Yao S, Cottam HB, Chan M, Ramos I, Eggink D, Heshmati M, Krammer F, Messer K, Pu M, Fernandez-Sesma A, Palese P, Carson DA.

J Virol. 2015 Mar;89(6):3221-35. doi: 10.1128/JVI.03337-14. Epub 2015 Jan 7.

4.

Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis.

Ato M, Takahashi Y, Fujii H, Hashimoto S, Kaji T, Itamura S, Horiuchi Y, Arakawa Y, Tashiro M, Takemori T.

Vaccine. 2013 Apr 19;31(17):2184-90. doi: 10.1016/j.vaccine.2013.02.016. Epub 2013 Feb 19.

PMID:
23434386
5.

Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine.

Geeraedts F, ter Veer W, Wilschut J, Huckriede A, de Haan A.

Vaccine. 2012 Oct 5;30(45):6501-7. doi: 10.1016/j.vaccine.2012.07.036. Epub 2012 Jul 27.

PMID:
22841974
6.

Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.

Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF.

Eur J Immunol. 2012 Apr;42(4):863-9. doi: 10.1002/eji.201041225.

7.

Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A.

PLoS Pathog. 2008 Aug 29;4(8):e1000138. doi: 10.1371/journal.ppat.1000138.

8.

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

Quan FS, Huang C, Compans RW, Kang SM.

J Virol. 2007 Apr;81(7):3514-24. Epub 2007 Jan 24.

9.

Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.

Chua BY, Wong CY, Mifsud EJ, Edenborough KM, Sekiya T, Tan AC, Mercuri F, Rockman S, Chen W, Turner SJ, Doherty PC, Kelso A, Brown LE, Jackson DC.

MBio. 2015 Oct 27;6(6):e01024-15. doi: 10.1128/mBio.01024-15.

10.

Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.

Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC.

J Virol. 2014 Nov;88(22):13418-28. doi: 10.1128/JVI.01219-14. Epub 2014 Sep 10.

11.

Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity.

Hong DK, Chang S, Botham CM, Giffon TD, Fairman J, Lewis DB.

J Virol. 2010 Dec;84(24):12691-702. doi: 10.1128/JVI.00769-10. Epub 2010 Oct 13.

12.

Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB/c mice.

Zhang AJ, Li C, To KK, Zhu HS, Lee AC, Li CG, Chan JF, Hung IF, Yuen KY.

Clin Vaccine Immunol. 2014 Apr;21(4):570-9. doi: 10.1128/CVI.00816-13. Epub 2014 Feb 12.

13.

Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.

Kulkarni RR, Rasheed MA, Bhaumik SK, Ranjan P, Cao W, Davis C, Marisetti K, Thomas S, Gangappa S, Sambhara S, Murali-Krishna K.

J Virol. 2014 Dec;88(24):13990-4001. doi: 10.1128/JVI.02273-14. Epub 2014 Sep 24.

14.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8. Epub 2007 Feb 15.

PMID:
17337102
15.

Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC.

J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6.

16.

Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.

Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, Compans RW, York I, Kang SM, Donis RO.

Clin Vaccine Immunol. 2011 Dec;18(12):2010-7. doi: 10.1128/CVI.05206-11. Epub 2011 Oct 26.

17.

Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus.

Di Mario G, Soprana E, Gubinelli F, Panigada M, Facchini M, Fabiani C, Garulli B, Basileo M, Cassone A, Siccardi A, Donatelli I, Castrucci MR.

Pathog Glob Health. 2017 Mar;111(2):69-75. doi: 10.1080/20477724.2016.1275464. Epub 2017 Jan 12.

PMID:
28081672
18.

Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 Influenza A virus induces protective immunity in mice.

Prabakaran M, Meng T, He F, Yunrui T, Qiang J, Lin RT, Kwang J.

Clin Vaccine Immunol. 2011 Sep;18(9):1582-5. doi: 10.1128/CVI.05114-11. Epub 2011 Jul 13.

19.

Programming the magnitude and persistence of antibody responses with innate immunity.

Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, García-Sastre A, Compans R, Pulendran B.

Nature. 2011 Feb 24;470(7335):543-7. doi: 10.1038/nature09737.

20.

Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.

Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.

J Med Virol. 2010 Jan;82(1):128-37. doi: 10.1002/jmv.21670.

PMID:
19950232

Supplemental Content

Support Center